Development and validation of a respiratory syncytial virus multiplex immunoassay
Authors:
- Patrick MarsallPMPatrick Marsall
- Madeleine FandrichMFMadeleine Fandrich
- Johanna GriesbaumJGJohanna Griesbaum
- Manuela HarriesMHManuela Harries
- Berit LangeBLBerit Lange
- RESPINOW Study ConsortiumRCRESPINOW Study Consortium
- Stephanie AscoughSAStephanie Ascough
- Pete DayanandaPDPete Dayananda
- Christopher ChiuCCChristopher Chiu
- Jonathan RemppisJRJonathan Remppis
- Tina GanzenmuellerTGTina Ganzenmueller
- Hanna RenkHRHanna Renk
Open Access
- 8 February 2024
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 52 (2) , 597-609
Abstract
Purpose: Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. While vaccines and monoclonal therapeutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses antibody titers toward the post-F, Nucleoprotein, and a diverse mix of G proteins. Methods: A bead-based multiplex RSV immunoassay was developed, technically validated to standard FDA bioanalytical guidelines, and clinically validated using samples from human challenge studies. RSV antibody titers were then investigated in children aged under 2 and a population-based cohort. Results: Technical and clinical validation showed outstanding performance, while methodological developments enabled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody responses within population cohorts. Conclusion: Overall, the developed assay shows robust performance, is scalable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies.Keywords
All Related Versions
Funding Information
- Horizon 2020 Framework Programme (101003480 CORESMA, 101003480 CORESMA)
- Initiative and Networking Fund of the Helmholtz Association of German Research Centres (SO-096 MuSPAD)
- Bundesministerium für Forschung, Technologie und Raumfahrt (031L0298A RESPINOW, 031L0298A RESPINOW)
- Network University Medicine (01KX2121 IMMUNEBRIDGE)
- Initiative and Networking Fund of the Helmholtz Association (LOKI)
- Medical Research Council (G0902266)
- Wellcome Trust (087805/Z/08/Z)
- Kwok Foundation
This publication has 43 references indexed in Scilit:
- Systematic reference sample generation for multiplexed serological assaysScientific Reports, 2013
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyScience, 2013
- Respiratory Syncytial Virus—A Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2013
- Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: Children and elderlyJournal of Virological Methods, 2010
- Prospects for Defined Epitope Vaccines for Respiratory Syncytial VirusFuture Microbiology, 2010
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsNew England Journal of Medicine, 2005
- Variation in severity of respiratory syncytial virus infections with subtypeThe Journal of Pediatrics, 1990
- The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.Proceedings of the National Academy of Sciences, 1987
- Characterization of the 10 proteins of human respiratory syncytial virus: Identification of a fourth envelope-associated proteinVirus Research, 1985